1. A single early-in-life antibiotic course increases susceptibility to DSS-induced colitis
- Author
-
Guillermo I. Perez-Perez, Martin J. Blaser, Victoria E. Ruiz, Ceren Özkul, Thomas Battaglia, Claire Roubaud-Baudron, Joseph Xu, Ken Cadwell, Hacettepe University = Hacettepe Üniversitesi, New York University School of Medicine, NYU System (NYU), Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle de Gérontologie Clinique [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Hôpital Xavier Arnozan, Skirball Institute of Biomolecular Medicine, New York University [New York] (NYU), NYU System (NYU)-NYU System (NYU), New York University Langone Medical Center (NYU Langone Medical Center), WINLAB Rutgers University, Rutgers, The State University of New Jersey [New Brunswick] (RU), Rutgers University System (Rutgers)-Rutgers University System (Rutgers), and Roubaud-Baudron, Claire
- Subjects
0301 basic medicine ,Pulsed antibiotic treatment ,Antibiotics ,lcsh:Medicine ,Disease ,Childhood antibiotic use ,Inflammatory bowel disease ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,Intestinal Mucosa ,Genetics (clinical) ,DSS-induced colitis ,medicine.diagnostic_test ,Dextran Sulfate ,Age Factors ,Biodiversity ,T-Lymphocytes, Helper-Inducer ,Colitis ,3. Good health ,Anti-Bacterial Agents ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Molecular Medicine ,Disease Susceptibility ,Macrolide ,medicine.drug ,lcsh:QH426-470 ,medicine.drug_class ,Tylosin ,digestive system ,Permeability ,Flow cytometry ,03 medical and health sciences ,Immune system ,Genetics ,medicine ,Animals ,Molecular Biology ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,Gastrointestinal microbiota ,business.industry ,Research ,lcsh:R ,Amoxicillin ,medicine.disease ,Gastrointestinal Microbiome ,Disease Models, Animal ,stomatognathic diseases ,lcsh:Genetics ,030104 developmental biology ,chemistry ,Immunology ,Dysbiosis ,business ,030217 neurology & neurosurgery - Abstract
Background There is increasing evidence that the intestinal microbiota plays a crucial role in the maturation of the immune system and the prevention of diseases during childhood. Early-life short-course antibiotic use may affect the progression of subsequent disease conditions by changing both host microbiota and immunologic development. Epidemiologic studies provide evidence that early-life antibiotic exposures predispose to inflammatory bowel disease (IBD). Methods By using a murine model of dextran sodium sulfate (DSS)-induced colitis, we evaluated the effect on disease outcomes of early-life pulsed antibiotic treatment (PAT) using tylosin, a macrolide and amoxicillin, a beta-lactam. We evaluated microbiota effects at the 16S rRNA gene level, and intestinal T cells by flow cytometry. Antibiotic-perturbed or control microbiota were transferred to pups that then were challenged with DSS. Results A single PAT course early-in-life exacerbated later DSS-induced colitis by both perturbing the microbial community and altering mucosal immune cell composition. By conventionalizing germ-free mice with either antibiotic-perturbed or control microbiota obtained 40 days after the challenge ended, we showed the transferrable and direct effect of the still-perturbed microbiota on colitis severity in the DSS model. Conclusions The findings in this experimental model provide evidence that early-life microbiota perturbation may increase risk of colitis later in life.
- Published
- 2020